<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent evidence strongly argues for a pathogenic role of <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> and 11β-<z:chebi fb="0" ids="35350">hydroxysteroid</z:chebi> dehydrogenase type 1 (11β-HSD1) in <z:hpo ids='HP_0001513'>obesity</z:hpo> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, a cluster of risk factors for <z:e sem="disease" ids="C0003972" disease_type="Disease or Syndrome" abbrv="ascvd">atherosclerotic cardiovascular disease</z:e> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) that includes <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (IR), <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This has been partially prompted not only by the striking clinical resemblances between the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:e sem="disease" ids="C0010481" disease_type="Disease or Syndrome" abbrv="">Cushing's syndrome</z:e> (a state characterized by <z:hpo ids='HP_0001578'>hypercortisolism</z:hpo> that associates with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> components) but also from monogenic <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> for the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (e.g. the leptin-deficient ob/ob mouse or the leptin-resistant <z:chebi fb="3" ids="16646">Zucker</z:chebi> rat) that display overall increased secretion of <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>However, systemic circulating <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> are not elevated in <z:mp ids='MP_0001261'>obese</z:mp> patients and/or patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The study of the role of 11β-HSD system shed light on this conundrum, showing that local <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> are finely regulated in a tissue-specific manner at the pre-receptor level </plain></SENT>
<SENT sid="4" pm="."><plain>The system comprises two microsomal enzymes that either activate <z:chebi fb="11" ids="16962">cortisone</z:chebi> to <z:chebi fb="1" ids="17650">cortisol</z:chebi> (11β-HSD1) or inactivate <z:chebi fb="1" ids="17650">cortisol</z:chebi> to <z:chebi fb="11" ids="16962">cortisone</z:chebi> (11β-HSD2) </plain></SENT>
<SENT sid="5" pm="."><plain>Transgenic <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e>, knockout (KO) for HSD11B1 or with HSD11B1 or HSD11B2 overexpression, specifically targeted to the liver or adipose tissue, have been developed and helped unravel the currently undisputable role of the enzymes in <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> pathophysiology, in each of its isolated components and in their prevention </plain></SENT>
<SENT sid="6" pm="."><plain>In the transgenic HSD11B1 overexpressing models, different features of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:hpo ids='HP_0001513'>obesity</z:hpo> are replicated </plain></SENT>
<SENT sid="7" pm="."><plain>HSD11B1 gene deficiency or HSD11B2 gene overexpression associates with improvements in the metabolic profile </plain></SENT>
<SENT sid="8" pm="."><plain>In face of these demonstrations, research efforts are now being turned both into the inhibition of 11β-HSD1 as a possible pharmacological target and into the role of dietary habits on the establishment or the prevention of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, <z:hpo ids='HP_0001513'>obesity</z:hpo> and T2DM through 11β-HSD1 modulation </plain></SENT>
<SENT sid="9" pm="."><plain>We intend to review and discuss 11β-HSD1 and <z:hpo ids='HP_0001513'>obesity</z:hpo>, the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and T2DM and to highlight the potential of its inhibition for therapeutic or prophylactic approaches in those <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e> </plain></SENT>
</text></document>